Castleark Management LLC Galapagos Nv Transaction History

Castleark Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$122.47 - $213.56 $286,579 - $499,730	-2,340 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$143.0 - $274.03 $105,820 - $202,782	-740 Reduced 24.03%	2,340 $458,000
Q3 2019 Nov 15, 2019	SELL	$130.44 - $187.64 $726,550 - $1.05 Million	-5,570 Reduced 64.39%	3,080 $470,000
Q2 2019 Aug 13, 2019	BUY	$111.45 - $128.93 $41,236 - $47,704	370 Added 4.47%	8,650 $1.12 Million
Q4 2018 Feb 12, 2019	SELL	$87.81 - $110.65 $393,388 - $495,712	-4,480 Reduced 35.11%	8,280 $760,000
Q3 2018 Nov 15, 2018	BUY	$90.63 - $120.22 $261,920 - $347,435	2,890 Added 29.28%	12,760 $1.44 Million
Q2 2018 Aug 15, 2018	BUY	$88.4 - $105.34 $279,874 - $333,506	3,166 Added 47.23%	9,870 $910,000
Q1 2018 May 15, 2018	SELL	$94.51 - $120.23 $6,237 - $7,935	-66 Reduced 0.97%	6,704 $669,000
Q4 2017 Feb 15, 2018	SELL	$84.48 - $104.02 $262,310 - $322,982	-3,105 Reduced 31.44%	6,770 $635,000
Q3 2017 Nov 15, 2017	BUY	$73.17 - $103.47 $722,553 - $1.02 Million	9,875	9,875 $1.01 Million

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.87B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.